CONCLUSIONS: While fertility and sexual health may not immediately be a concern for cancer patients, it is important for cancer survivorship and return to normalcy. The data presented highlights a discrepancy in less information being available for males compared to females. Overall, there is a need to improve the quality and accessibility of fertility and sexual health information for both genders on all NCIdesignated CC websites.
INTRODUCTION AND OBJECTIVES: Increased evidence suggests that genetics involved in male infertility is important to neural development and cognitive function. However, whether male infertility and lower cognitive function is due to shared genetic abnormalities remains unknown. Further understanding this potential link could aid in counseling couples and direct future treatment plans for affected men. This study serves to update our previous series to explore the association between male infertility and cognitive function, anxiety, and depressive symptoms.
METHODS: A total of 70 men presenting to a single academic andrology practice were prospectively identified and enrolled in the study. Of these, 42 men presented with nonobstructive azoospermia (NOA) or severe oligospermia (<5 million sperm/mL) and 28 with proven fertility (control group). All patients completed the validated Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7) questionnaire, and Test of Nonverbal Intelligence, 4th edition (TONI-4) IQ evaluation under the supervision of a technician trained to administer the tests. Patients were asked to provide their occupation, and U.S. Census Bureau statistics were used to estimate incomes by occupation. TONI-4 results were analyzed by a psychologist in blinded fashion to determine final IQ scores. Test and questionnaire results were compared between groups.
RESULTS: MeanAESD age in the entire cohort was 38.5AE7.9 years, and in the infertile and control subgroups was 36.1AE7.3 and 42.0AE7.5 years, respectively. Mean estimated income in the infertile and control groups was $76, 474AE$46, 195 and $97, 340AE54, 836, respectively (p[0.14) . A small majority (22/41, 53.7%) of the infertile group had at least a bachelor's degree while 14/28 (50.0%) of the control group had the same (p[0.77). The mean IQ for the infertile cohort was 99.2AE8.2 points, whereas the mean IQ for the control group was 106.3AE9.1 points (mean diff: 7.1 points; p[0.001). The mean PHQ-9 score within the infertile group was 3.9AE4.1 points and in the control group 3.8AE4.9 points (p[0.89). Mean GAD-7 scores were 3.7AE3.3 points in the infertile group and 3.8AE4.3 points in the control group (p[0.98). These latter test results ensured that other psychological factors did not impact the IQ findings.
CONCLUSIONS: Our extended data confirms that severe male factor infertility may predispose to lower cognitive function. Additional work examining this relationship is essential to better establish the link between infertility and cognitive function, and to determine whether affected men demonstrate specific genetic defects.
Source of Funding: A.W.P. is a National Institutes of Health K08 Scholar supported by a Mentored Career Development Award (K08DK115835-01) from the National Institute of Diabetes and Digestive and Kidney Diseases. This work is also supported in part through a Urology Care Foundation Rising Stars in Urology Award (to A.W.P.).
PD29-07 PATERNAL MEDICATION USE AND COMORBIDITY IN THE UNITED STATES: A REVIEW OF OVER 1 MILLION LIVE BIRTHS
Andrew Sun*, Shufeng Li, Chiyuan Zhang, Michael Eisenberg, Stanford, CA INTRODUCTION AND OBJECTIVES: While the effects of maternal medication use and comorbidity on pregnancy outcomes have been studied extensively, little research has been done on the consequences of paternal exposures at the time of conception. Compounding this, there is no published data on paternal comorbidity and medication exposures to help guide investigation into associations with fetal outcomes.
METHODS: IBM Marketscan is a national employer-based insurance claims database with information from over 100 million individuals. We identified 982,862 unique men who had a child born between 2008 and 2016 (1,130,738 live births) . We then looked for the presence of diagnoses and medications in the months prior to the estimated date of conception for each birth.
RESULTS: Fathers for 50.1% of all births were on a prescription medication at the time of conception. The prevalence of this increased with age, from 43.9% in fathers 20-29 years old to 61.3% in fathers over 50 years old. The proportion of fathers on a medication increased from 49.1% in 2008 to 55.0% in 2016. Fathers taking medications tended to have more physician visits per year (52.4% with 2þ visits per year vs 19.6%) and were more likely to be diagnosed with obesity (65.0% of all obese fathers) or be a smoker (63.8% of all smoker fathers). The most commonly used medication classes were antibiotics (29.3%) and central nervous system agents (22.4%). The most common diseases at the time of conception were of the respiratory system (45.3%) and musculoskeletal system (40.9%). The overall health of fathers declined over the study period, with the percentage of fathers with a Charlson Comorbidity Index of 0 trending from 92.1% in 2008 to 83.7% in 2016.
CONCLUSIONS: The prevalence of paternal medication use and comorbidity has never been reported in the United States,
